Browse > Article
http://dx.doi.org/10.3340/jkns.2021.0077

Neurotoxicity of Paclitaxel and Rapamycin in a Rat Model with Transient Blood-Brain Barrier Opening  

Cho, Won-Sang (Department of Neurosurgery, Seoul National University Hospital)
Choi, Jung Hoon (Department of Anatomy, College of Veterinary Medicine, Kangwon National University)
Kwon, O-Ki (Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
Publication Information
Journal of Korean Neurosurgical Society / v.65, no.2, 2022 , pp. 180-185 More about this Journal
Abstract
Objective : Drug-eluting stents and balloons are occasionally used to reduce restenosis in medically intractable intracranial atherosclerotic stenosis. The authors aimed to determine whether such drugs can cause neurotoxicity due to local effects in a rat model. Methods : Intra-arterial catheters were placed in the right common carotid artery of rats. Mannitol was injected to transiently open the brain-blood barrier (BBB), followed by high-dose drug (paclitaxel and rapamycin) injection. The optimal time interval of transient BBB opening for maximal drug penetration was determined to be 10 minutes. Paclitaxel and rapamycin were intra-arterially administered in various doses. All the rats were neurologically evaluated, and their brain tissues were histologically examined. Results : Neither neurological deficits nor histological abnormalities were observed in all the rats. Conclusion : Paclitaxel and rapamycin did not cause neurotoxicity in a rat model with transient BBB opening.
Keywords
Intracranial atherosclerotic stenosis; Neurotoxicity; Paclitaxel; Rapamycin; Restenosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kim SJ, Kim YJ, Ko JH : Long term outcome of in-stent stenosis after stent assisted coil embolization for cerebral aneurysm. J Korean Neurosurg Soc 62 : 536-544, 2019   DOI
2 Maramattom BV, Wijdicks EF : Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology 63 : 1958-1959, 2004   DOI
3 Reagan-Shaw S, Nihal M, Ahmad N : Dose translation from animal to human studies revisited. FASEB J 22 : 659-661, 2008   DOI
4 Velasco R, Bruna J : Taxane-induced peripheral neurotoxicity. Toxics 3 : 152-169, 2015   DOI
5 Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H : Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 : 472-476, 1986   DOI
6 Levy EI, Hanel RA, Howington JU, Nemes B, Boulos AS, Tio FO, et al. : Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response. J Neurosurg 100 : 688-694, 2004   DOI
7 Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. : Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365 : 993-1003, 2011   DOI
8 Gupta R, Al-Ali F, Thomas AJ, Horowitz MB, Barrow T, Vora NA, et al. : Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 37 : 2562-2566, 2006   DOI
9 Kim J, Ban SP, Kim YD, Kwon OK : Long-term outcomes of drug-eluting stent implantation in patients with symptomatic extra- and intracranial atherosclerotic stenoses. J Cerebrovasc Endovasc Neurosurg 22 : 216-224, 2020   DOI
10 Levy EI, Hanel RA, Tio FO, Garlick DS, Bailey L, Cunningham MR, et al. : Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. Neurosurgery 59 : 925-933; discussion 933-934, 2006   DOI
11 Qureshi AI, Kirmani JF, Hussein HM, Harris-Lane P, Divani AA, Suri MF, et al. : Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis. Neurosurgery 59 : 1044-1051; discussion 1051, 2006   DOI
12 Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC : Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20(4 Suppl 3) : 1-15, 1993
13 Abou-Chebl A, Bashir Q, Yadav JS : Drug-eluting stents for the treatment of intracranial atherosclerosis: initial experience and midterm angiographic follow-up. Stroke 36 : e165-e168, 2005
14 Steinfort B, Ng PP, Faulder K, Harrington T, Grinnell V, Sorby W, et al. : Midterm outcomes of paclitaxel-eluting stents for the treatment of intracranial posterior circulation stenoses. J Neurosurg 106 : 222-225, 2007   DOI
15 Waksman R, Pakala R : Drug-eluting balloon: the comeback kid? Circ Cardiovasc Interv 2 : 352-358, 2009   DOI
16 Barnard ZR, Alexander MJ : Update in the treatment of intracranial atherosclerotic disease. Stroke Vasc Neurol 5 : 59-64, 2019   DOI
17 Gheith O, Cerna M, Halim MA, Nampoory N, Al-Otaibi T, Nair P, et al. : Sirolimus-induced combined posterior reversible encephalopathy syndrome and lymphocytic pneumonitis in a renal transplant recipient: case report and review of the literature. Exp Clin Transplant 15(Suppl 1) : 170-174, 2017
18 Park S, Lee DG, Chung WJ, Lee DH, Suh DC : Long-term outcomes of drug-eluting stents in symptomatic intracranial stenosis. Neurointervention 8 : 9-14, 2013   DOI